The development and commercialization of biologics—including monoclonal antibodies (mAbs), recombinant proteins, fusion proteins, and vaccines—demand sophisticated bioprocess engineering and robust Chemistry, Manufacturing, and Controls (CMC) strategies. From cell line development to commercial cGMP batch production, even minor process variations can impact product purity, yield, and regulatory approval.
At OAAK Biosolutions, we offer expert biologics manufacturing consulting services designed to optimize upstream bioprocessing, streamline downstream purification, and accelerate technology transfer. We collaborate with biopharmaceutical companies to mitigate manufacturing risks, improve batch yields, and maintain global regulatory compliance.
Our consulting services address critical technical hurdles across both upstream and downstream bioprocessing lifecycles.
Maximizing cell viability, titer yields, and process reproducibility is essential for cost-effective commercial supply.
Cell Line & Media Optimization: Selecting robust expression systems (CHO, HEK293, microbial) and customizing feed strategies.
Bioreactor Scale-Up: Transitioning from bench-scale shake flasks to stainless steel or single-use bioreactors (SUBs).
Process Analytical Technology (PAT): Implementing real-time monitoring for dissolved oxygen, pH, metabolite levels, and cell density.
High-purity isolation of complex biological molecules requires precise recovery techniques.
Chromatography & Filtration Strategy: Designing multi-step purification schemes (Affinity, IEX, HIC, SEC) and tangential flow filtration (TFF).
Impurities & Host Cell Protein (HCP) Removal: Resolving aggregation issues and eliminating DNA, viral contaminants, and HCPs.
Single-Use Assemblies: Integrating single-use manifolds and filtration units to lower cross-contamination risk and turnaround times.
Seamlessly transferring bioprocesses between facilities or to Contract Development and Manufacturing Organizations (CDMOs) prevents costly delays.
CDMO Selection & Auditing: Vetting biological manufacturing partners based on capacity, technical capabilities, and cGMP history.
Technology Transfer Protocols: Standardizing master batch records (MBRs), analytical method transfer, and critical process parameters (CPPs).
On-Site Operational Support: Providing technical oversight during campaign execution and process validation (PV) runs.
Ensuring product consistency when making process changes during clinical phases or post-approval.
Analytical Characterization: Establishing critical quality attributes (CQAs) using mass spectrometry, HPLC, and bioassays.
Comparability Protocols: Demonstrating batch-to-batch consistency following manufacturing scale-up or facility moves.
Regulatory Submissions: Structuring biological Module 3 CMC sections for IND, BLA, and EMA filings.
Bioprocess Audit & Assessment: Evaluating baseline yields, purification steps, and analytical methods for scale-up gaps.
Process Optimization Plan: Defining CPPs and CQAs through Design of Experiments (DoE) methodology.
Scale-Up & Tech Transfer: Transferring optimized processes to cGMP manufacturing suites with continuous monitoring.
Validation & BLA Readiness: Overseeing Process Performance Qualification (PPQ) batches and regulatory dossier preparation.
Maximize upstream expression levels and cellular productivity by optimizing media formulations, bioreactor parameters, and automated feed-batch strategies.
Prevent molecular instability and product degradation by refining downstream chromatography, tangential flow filtration (TFF), and formulation buffer conditions.
Accelerate tech transfer to CDMO partners using standardized master batch records, comprehensive risk assessments (FMEA), and robust scale-up protocols.
Ensure seamless IND and BLA regulatory approvals by aligning analytical characterization, comparability studies, and Module 3 filings with FDA and EMA standards.
We support a broad spectrum of biologics, including monoclonal antibodies (mAbs), bispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), fusion proteins, and viral/non-viral vaccines.
Single-use bioreactors and filtration bags eliminate the need for complex cleaning validation (CIP/SIP), reduce batch turnaround times, decrease capital expenditure (CapEx) for initial facility setups, and lower cross-contamination risk.
We design comprehensive analytical testing protocols (evaluating structure, potency, purity, and stability profile) to demonstrate to regulatory bodies that process changes do not adversely affect product safety or efficacy.
Maximize titers, optimize purification, and secure cGMP regulatory approvals. Partner with OAAK Biosolutions for biological process development and CMC excellence.